Biomarin Pharmaceutical (BMRN) Operating Income (2009 - 2026)
Biomarin Pharmaceutical (BMRN) posted Operating Income of $129.6 million for Q1 2026, up 390.61% on a QoQ basis from -$44.6 million in Q4 2025, and down 42.1% year-over-year from $223.9 million in Q1 2025.
Biomarin Pharmaceutical (BMRN) Operating Income (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical's Operating Income history runs 18 years deep, the most recent figure standing at $129.6 million for Q1 2026.
- Quarterly Operating Income fell 42.1% year-over-year to $129.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $315.2 million (down 49.13% YoY) and the FY2025 annual result came in at $409.5 million, down 15.43% from the prior year.
- Operating Income was $129.6 million for Q1 2026 at Biomarin Pharmaceutical, up from -$44.6 million in the prior quarter.
- Across five years, Operating Income topped out at $276.9 million in Q2 2025 and bottomed at -$46.7 million in Q3 2025.
- A 5-year average of $80.6 million and a median of $65.6 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income surged 1362.93% — and 2025, when it slumped 141.0%.
- Biomarin Pharmaceutical's Operating Income stood at -$13.1 million in 2022, then jumped by 308.43% to $27.3 million in 2023, then jumped by 491.69% to $161.4 million in 2024, then slumped by 127.64% to -$44.6 million in 2025, then surged by 390.61% to $129.6 million in 2026.
- Business Quant data shows BMRN's Operating Income at $129.6 million in Q1 2026, -$44.6 million in Q4 2025, and -$46.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Biomarin Pharmaceutical | 11.33 Bn | 9.11 Bn | 571.21 Mn | 129.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 129.64 Mn |
| Dec 31, 2025 | -44.61 Mn |
| Sep 30, 2025 | -46.69 Mn |
| Jun 30, 2025 | 276.89 Mn |
| Mar 31, 2025 | 223.89 Mn |
| Dec 31, 2024 | 161.41 Mn |
| Sep 30, 2024 | 113.89 Mn |
| Jun 30, 2024 | 120.45 Mn |
| Mar 31, 2024 | 88.46 Mn |
| Dec 31, 2023 | 27.28 Mn |
| Sep 30, 2023 | 30.53 Mn |
| Jun 30, 2023 | 65.57 Mn |
| Mar 31, 2023 | 62.40 Mn |
| Dec 31, 2022 | -13.09 Mn |
| Sep 30, 2022 | -2.42 Mn |
| Jun 30, 2022 | 39.15 Mn |
| Mar 31, 2022 | 137.33 Mn |
| Dec 31, 2021 | -65.88 Mn |
| Sep 30, 2021 | -53.22 Mn |
| Jun 30, 2021 | 11.67 Mn |